LIR Life Sciences Corp. reports developments in preclinical drug-delivery research centered on needle-free transdermal transport of therapeutic molecules. Company updates focus on cell-penetrating peptide formulations, protamine-enhanced skin transport, GLP/GIP-based metabolic therapy models, ex vivo porcine skin work, and controlled animal studies designed to evaluate biological activity and feasibility rather than therapeutic efficacy.
Recurring news also covers peptide design and optimization work, structure-activity research, formulation studies, and collaboration agreements with research and development partners, including Neuland Laboratories and Resilience BioSciences.
LIR Life Sciences (OTC:BBCMF) has launched a controlled ex vivo porcine skin study to test whether protamine enhances transdermal transport of macromolecular therapeutics. The experiment will test fluorescently labeled payloads from ~5 kDa to ~150 kDa versus matched controls, use confocal microscopy, and collect timepoint samples to evaluate penetration depth and distribution as feasibility data to guide future needle‑free delivery development.
LIR Life Sciences (OTC:BBCMF) entered a six-month Technology Development Collaboration Agreement with Resilience BioSciences to support preclinical work. LIR will conduct ex vivo porcine skin and formulation studies at RBI's facilities located at adMare BioInnovations within UBC's Pharmaceutical Sciences Building. The Company will pay $5,000 per month under the initial term.
The collaboration emphasizes access to academic expertise, modern lab infrastructure, and translational preclinical validation to advance LIR's delivery-technology programs.
LIR Life Sciences (OTC:BBCMF) has begun Project Phase 2 peptide design with Neuland Laboratories to optimize next-generation cell-penetrating peptides for its transdermal delivery platform. Phase 2 focuses on structure-activity relationship (SAR) analysis of protamine-based sequences to identify third‑generation candidates with improved transport, synthetic efficiency and formulation flexibility.
Neuland and LIR will refine peptide structures and prioritize synthesis targets to inform later synthesis, formulation and biological testing stages.
LIR Life Sciences (OTC:BBCMF) reported positive interim preclinical results from a comparative mouse study of a CPP-enabled, needle-free topical semaglutide formulation. Treated animals showed reduced blood glucose after an oral glucose challenge versus untreated controls, with a flattened glucose curve approaching the injectable comparator.
Findings suggest the CPP transdermal platform may deliver pharmacologically meaningful levels of GLP/GIP-based peptides across skin and support further dose refinement and continuation of comparative studies.
LIR Life Sciences (OTC:BBCMF) launched a controlled comparative animal study to test cell-penetrating peptide (CPP)-mediated, needle-free transdermal delivery of second-generation GLP/GIP-based obesity therapies. Animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a glucose tolerance test to compare blood-glucose control over time. The study is intended to evaluate broader applicability of the CPP transdermal platform and to guide molecule selection for potential IND-enabling work. Separately, the company engaged ICP Securities for automated market making at C$7,500/month, starting January 13, 2026, for an initial four-month term.
LIR Life Sciences (OTC:BBCMF) announced a services agreement with Neuland Laboratories to develop and test cell-penetrating peptides (CPPs) for its transdermal GLP-1/GIP platform. The agreement covers defined Phase 1 R&D activities with an aggregate Phase 1 budget of US$230,000, subject to adjustment based on material quantities, and contemplates possible future phases on mutual commercial terms. Neuland operates cGMP peptide facilities with FDA and other international approvals. Separately, LIR engaged Fairfax Partners for a three-month digital marketing program with a total budget of US$150,000.
Blackbird Critical Metals Corp. (CSE: BBRD) (OTCQB: BBCMF) has released new sampling results from its Tyee Critical Minerals Project in Quebec. The company's Big Tio target yielded promising results, with 10 new samples at the northern end averaging 35.8% titanium dioxide (TiO2) and one sample at the southern end returning 34.3% TiO2. These findings suggest potential massive ilmenite mineralization over a 1400 m strike length.
Additionally, Blackbird has filed a 43-101 technical report on the Tyee Project. The company also announced a management change, with Allan Larmour replacing Dr. Jacob Verbaas as Interim CEO.
Blackbird Critical Metals Corp. (CSE: BBRD, FSE: N79, OTCQB: BBCMF) announced updates on their ground exploration program at the Tyee Critical Metals Project in Quebec. The SkyTEM survey identified additional targets, and massive ilmenite was sampled at the Big Tio and NS Trend targets. The Big Tio target revealed massive ilmenite with accessory sulphide minerals and magnetite, aiding future exploration planning. Additional ilmenite samples were found at the NS Trend, which is largely obscured by overburden but suggests a strike length of up to 3 km. The findings validate Blackbird's confidence in the project's potential.
Blackbird Critical Metals Corp. (CSE: BBRD; FSE: N79; OTCQB: BBCMF) announces a ground exploration program for the Tyee Critical Metals Project in Quebec. The program aims to assess 12 new SkyTEM EM targets and evaluate 24 priority drill collars, focusing on titanium and nickel-copper mineralization. The exploration, scheduled from June 6-23, 2024, seeks to validate previous findings and improve drilling efficiency. The company extends its marketing contract with i2i Marketing Group for three months or until funds of $100,000 are exhausted.
Blackbird Critical Metals Corp. announces the receipt of an exploration camp permit for its maiden drill program, reducing travel distance and costs. The Company has engaged Groundtruth Drilling as its contractor, expecting to test a minimum of 6 targets. Dr. Jacob Verbaas, Interim CEO, confirms plans for 20 drill holes to test near-surface titanium and nickel occurrences.